Association of physician specialty and medical therapy for benign prostatic hyperplasia

Leona C. Han, Simon P. Kim, Cary P. Gross, Joseph S. Ross, Holly K. Van Houten, Marc C. Smaldone, Amy E. Krambeck, Nilay D Shah

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: Despite little available evidence to determine whether recently introduced selective α-1 blockers and 5-α reductase inhibitors (5-ARIs) are superior to the existing agents in treating benign prostatic hyperplasia (BPH), they are being increasingly prescribed. Objective: To describe the prescribing patterns of new and existing agents among patients with incident BPH after the introduction of several new agents and determine whether these varied by physician specialty. Research design: We analyzed a retrospective cohort from an administrative claims database from January 2004 through December 2010. Subjects: Patients diagnosed with incident BPH aged 40 years and above and those who received medical management. Measures: Receipt of medical therapy for incident BPH (ie, selective α-1 blockers [prazosin (released 1976), terazosin (1987), doxazosin (1990), tamsulosin (1997), alfuzosin (2003), silodosin (2009)] and 5-ARIs [finasteride (1992) and dutasteride (2002)]). Results: A total of 42,769 men with incident BPH received any selective α-1 blocker or 5-ARI. Tamsulosin and dutasteride were the most widely prescribed agents of their respective drug classes. Predicted probabilities showed that urologists were more likely to prescribe alfuzosin (24.0% vs. 7.8%; P<0.001) and silodosin (2.3% vs. 0.4%; P<0.001) when compared with primary care providers (PCPs) at 6 months after diagnosis. Urologists were more likely to prescribe 5-ARIs but less likely to prescribe older α-1 blockers (terazosin, prazosin, and doxazosin) than PCPs at 6 months postdiagnosis. Conclusions: Among insured patients diagnosed with BPH, our study suggests that the overall use of new agents is rising. In particular, urologists were more likely to prescribe newer selective α-1 blockers compared with PCPs.

Original languageEnglish (US)
Pages (from-to)128-136
Number of pages9
JournalMedical Care
Volume52
Issue number2
DOIs
StatePublished - Feb 2014

Fingerprint

Prostatic Hyperplasia
Terazosin
tamsulosin
Medicine
Physicians
Doxazosin
Primary Health Care
Prazosin
Therapeutics
Finasteride
Proxy
Oxidoreductases
Research Design
Databases
Pharmaceutical Preparations
Urologists

Keywords

  • administrative data
  • evidence base medicine
  • physician practice patterns
  • physician specialty
  • urologic diseases

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health

Cite this

Han, L. C., Kim, S. P., Gross, C. P., Ross, J. S., Van Houten, H. K., Smaldone, M. C., ... Shah, N. D. (2014). Association of physician specialty and medical therapy for benign prostatic hyperplasia. Medical Care, 52(2), 128-136. https://doi.org/10.1097/MLR.0000000000000078

Association of physician specialty and medical therapy for benign prostatic hyperplasia. / Han, Leona C.; Kim, Simon P.; Gross, Cary P.; Ross, Joseph S.; Van Houten, Holly K.; Smaldone, Marc C.; Krambeck, Amy E.; Shah, Nilay D.

In: Medical Care, Vol. 52, No. 2, 02.2014, p. 128-136.

Research output: Contribution to journalArticle

Han, LC, Kim, SP, Gross, CP, Ross, JS, Van Houten, HK, Smaldone, MC, Krambeck, AE & Shah, ND 2014, 'Association of physician specialty and medical therapy for benign prostatic hyperplasia', Medical Care, vol. 52, no. 2, pp. 128-136. https://doi.org/10.1097/MLR.0000000000000078
Han LC, Kim SP, Gross CP, Ross JS, Van Houten HK, Smaldone MC et al. Association of physician specialty and medical therapy for benign prostatic hyperplasia. Medical Care. 2014 Feb;52(2):128-136. https://doi.org/10.1097/MLR.0000000000000078
Han, Leona C. ; Kim, Simon P. ; Gross, Cary P. ; Ross, Joseph S. ; Van Houten, Holly K. ; Smaldone, Marc C. ; Krambeck, Amy E. ; Shah, Nilay D. / Association of physician specialty and medical therapy for benign prostatic hyperplasia. In: Medical Care. 2014 ; Vol. 52, No. 2. pp. 128-136.
@article{5f232ef576a445df9681eb4289680ce1,
title = "Association of physician specialty and medical therapy for benign prostatic hyperplasia",
abstract = "Background: Despite little available evidence to determine whether recently introduced selective α-1 blockers and 5-α reductase inhibitors (5-ARIs) are superior to the existing agents in treating benign prostatic hyperplasia (BPH), they are being increasingly prescribed. Objective: To describe the prescribing patterns of new and existing agents among patients with incident BPH after the introduction of several new agents and determine whether these varied by physician specialty. Research design: We analyzed a retrospective cohort from an administrative claims database from January 2004 through December 2010. Subjects: Patients diagnosed with incident BPH aged 40 years and above and those who received medical management. Measures: Receipt of medical therapy for incident BPH (ie, selective α-1 blockers [prazosin (released 1976), terazosin (1987), doxazosin (1990), tamsulosin (1997), alfuzosin (2003), silodosin (2009)] and 5-ARIs [finasteride (1992) and dutasteride (2002)]). Results: A total of 42,769 men with incident BPH received any selective α-1 blocker or 5-ARI. Tamsulosin and dutasteride were the most widely prescribed agents of their respective drug classes. Predicted probabilities showed that urologists were more likely to prescribe alfuzosin (24.0{\%} vs. 7.8{\%}; P<0.001) and silodosin (2.3{\%} vs. 0.4{\%}; P<0.001) when compared with primary care providers (PCPs) at 6 months after diagnosis. Urologists were more likely to prescribe 5-ARIs but less likely to prescribe older α-1 blockers (terazosin, prazosin, and doxazosin) than PCPs at 6 months postdiagnosis. Conclusions: Among insured patients diagnosed with BPH, our study suggests that the overall use of new agents is rising. In particular, urologists were more likely to prescribe newer selective α-1 blockers compared with PCPs.",
keywords = "administrative data, evidence base medicine, physician practice patterns, physician specialty, urologic diseases",
author = "Han, {Leona C.} and Kim, {Simon P.} and Gross, {Cary P.} and Ross, {Joseph S.} and {Van Houten}, {Holly K.} and Smaldone, {Marc C.} and Krambeck, {Amy E.} and Shah, {Nilay D}",
year = "2014",
month = "2",
doi = "10.1097/MLR.0000000000000078",
language = "English (US)",
volume = "52",
pages = "128--136",
journal = "Medical Care",
issn = "0025-7079",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Association of physician specialty and medical therapy for benign prostatic hyperplasia

AU - Han, Leona C.

AU - Kim, Simon P.

AU - Gross, Cary P.

AU - Ross, Joseph S.

AU - Van Houten, Holly K.

AU - Smaldone, Marc C.

AU - Krambeck, Amy E.

AU - Shah, Nilay D

PY - 2014/2

Y1 - 2014/2

N2 - Background: Despite little available evidence to determine whether recently introduced selective α-1 blockers and 5-α reductase inhibitors (5-ARIs) are superior to the existing agents in treating benign prostatic hyperplasia (BPH), they are being increasingly prescribed. Objective: To describe the prescribing patterns of new and existing agents among patients with incident BPH after the introduction of several new agents and determine whether these varied by physician specialty. Research design: We analyzed a retrospective cohort from an administrative claims database from January 2004 through December 2010. Subjects: Patients diagnosed with incident BPH aged 40 years and above and those who received medical management. Measures: Receipt of medical therapy for incident BPH (ie, selective α-1 blockers [prazosin (released 1976), terazosin (1987), doxazosin (1990), tamsulosin (1997), alfuzosin (2003), silodosin (2009)] and 5-ARIs [finasteride (1992) and dutasteride (2002)]). Results: A total of 42,769 men with incident BPH received any selective α-1 blocker or 5-ARI. Tamsulosin and dutasteride were the most widely prescribed agents of their respective drug classes. Predicted probabilities showed that urologists were more likely to prescribe alfuzosin (24.0% vs. 7.8%; P<0.001) and silodosin (2.3% vs. 0.4%; P<0.001) when compared with primary care providers (PCPs) at 6 months after diagnosis. Urologists were more likely to prescribe 5-ARIs but less likely to prescribe older α-1 blockers (terazosin, prazosin, and doxazosin) than PCPs at 6 months postdiagnosis. Conclusions: Among insured patients diagnosed with BPH, our study suggests that the overall use of new agents is rising. In particular, urologists were more likely to prescribe newer selective α-1 blockers compared with PCPs.

AB - Background: Despite little available evidence to determine whether recently introduced selective α-1 blockers and 5-α reductase inhibitors (5-ARIs) are superior to the existing agents in treating benign prostatic hyperplasia (BPH), they are being increasingly prescribed. Objective: To describe the prescribing patterns of new and existing agents among patients with incident BPH after the introduction of several new agents and determine whether these varied by physician specialty. Research design: We analyzed a retrospective cohort from an administrative claims database from January 2004 through December 2010. Subjects: Patients diagnosed with incident BPH aged 40 years and above and those who received medical management. Measures: Receipt of medical therapy for incident BPH (ie, selective α-1 blockers [prazosin (released 1976), terazosin (1987), doxazosin (1990), tamsulosin (1997), alfuzosin (2003), silodosin (2009)] and 5-ARIs [finasteride (1992) and dutasteride (2002)]). Results: A total of 42,769 men with incident BPH received any selective α-1 blocker or 5-ARI. Tamsulosin and dutasteride were the most widely prescribed agents of their respective drug classes. Predicted probabilities showed that urologists were more likely to prescribe alfuzosin (24.0% vs. 7.8%; P<0.001) and silodosin (2.3% vs. 0.4%; P<0.001) when compared with primary care providers (PCPs) at 6 months after diagnosis. Urologists were more likely to prescribe 5-ARIs but less likely to prescribe older α-1 blockers (terazosin, prazosin, and doxazosin) than PCPs at 6 months postdiagnosis. Conclusions: Among insured patients diagnosed with BPH, our study suggests that the overall use of new agents is rising. In particular, urologists were more likely to prescribe newer selective α-1 blockers compared with PCPs.

KW - administrative data

KW - evidence base medicine

KW - physician practice patterns

KW - physician specialty

KW - urologic diseases

UR - http://www.scopus.com/inward/record.url?scp=84892990067&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892990067&partnerID=8YFLogxK

U2 - 10.1097/MLR.0000000000000078

DO - 10.1097/MLR.0000000000000078

M3 - Article

VL - 52

SP - 128

EP - 136

JO - Medical Care

JF - Medical Care

SN - 0025-7079

IS - 2

ER -